{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.87","upperLimit":"49.88","value":"44.8"},{"groupId":"OG001","lowerLimit":"43.38","upperLimit":"52.84","value":"48.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"397"},{"groupId":"OG001","value":"447"}],"units":"Participants"}],"description":"Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \\>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Placebo+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG001","title":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin"}],"paramType":"NUMBER","populationDescription":"The ITT population was defined as all participants randomized to the Atezolizumab+Gemcitabine+Carboplatin/Cisplatin arm or the Placebo+Gemcitabine+Carboplatin/Cisplatin arm in Stages 1 and 2, whether or not the assigned study treatment was received. The measurable disease populations were defined as participants in the respective ITT populations with at least one measurable lesion according to RECIST v1.1 based on investigator assessment.","reportingStatus":"POSTED","timeFrame":"Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)","title":"Objective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}